| BACKGROUND
Allergic rhinoconjunctivitis is a very common chronic condition that can result in considerable morbidity and impairment of quality of life. 1, 2 The disease is triggered by exposure to seasonal and/or perennial allergens and, depending on the nature of the allergenic trigger(s) and patterns of exposure, symptoms may be persistent or intermittent. 3 Allergic rhinitis is typically characterized by symptoms of nasal obstruction, a watery nasal discharge, sneezing and itching, and there is often (but not invariably) involvement of the conjunctiva (allergic conjunctivitis), which manifests with itching, injection and tearing. 4 There may in addition be an impact on the ability to concentrate, on school and work performance, 5, 6 and interference with daily activities and sleep; furthermore, allergic rhinitis is a risk factor for the development of asthma. 7 Symptoms can, in many cases, be controlled with avoidance measures and pharmacological therapies such as oral, intranasal and topical (ophthalmic) H 1 -antihistamines, intranasal corticosteroids and antileukotrienes, as monotherapy or in combination. 8, 9 Allergen immunotherapy (AIT) is an additional potential treatment option, particularly for those with more troublesome disease which remains inadequately controlled despite avoidance measures and regular pharmacotherapy. [8] [9] [10] The problem of inadequately controlled allergic rhinoconjunctivitis, despite optimal medical treatment, continues to represent a therapeutic challenge in the majority of patients.
The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing Guidelines on AIT for Allergic
Rhinoconjunctivitis and this systematic review has been undertaken to inform the formulation of key clinical recommendations.
Specifically, we sought to assess the effectiveness, cost-effectiveness and safety of AIT in patients with allergic rhinoconjunctivitis. 11 
| METHODS
As our methods have been reported in detail in our published protocol, 12 we confine ourselves to a synopsis of the methods employed.
| Search strategy
A highly sensitive search strategy was developed and validated study design filters were applied to search nine electronic bibliographic databases. The search strategy was developed on OVID MEDLINE and then adapted for the other databases (see Appendix S1). In all cases, the databases were searched from inception to October 31, 2015 . Additional references were located through searching the references cited by the identified studies, and unpublished work, while research in progress was identified through discussion with experts in the field. We invited experts from a range of disciplines and regions to add to the list of included studies by identifying additional published and unpublished papers they were aware of and research in progress. There were no language restrictions employed; where possible, relevant literature was translated into English.
| Inclusion criteria
We focused on studies conducted on patients of any age with allergic rhinoconjunctivitis investigating the effect of AIT. See Box 1 for full details.
Box 1 Inclusion and exclusion criteria
Patient characteristics Studies conducted on patients of any age with a physician-confirmed diagnosis of allergic rhinoconjunctivitis or allergic rhinitis, plus evidence of clinically relevant allergic sensitization (eg, skin prick test or specific IgE).
| Study selection
All references were uploaded into the systematic review software DistillerSR and underwent initial de-duplication. Study titles were independently checked by two reviewers (SD and UN) according to the above selection criteria and categorized as included, not included or unsure. For those papers in the unsure category, we retrieved the abstract and recategorized as above. Any discrepancies were resolved through discussion and, if necessary, a third reviewer (AS) was consulted. Full-text copies of potentially relevant studies were obtained and their eligibility for inclusion independently assessed by two reviewers (SD and UN). Studies that did not fulfill all of the inclusion criteria were excluded.
| Quality assessment strategy
Quality assessments were independently carried out on each study by two reviewers (UN, SA, AA, MA, or TM) using a range of instruments. RCTs were assessed for generation of allocation sequence, concealment of allocation, baseline outcome measurements, baseline characteristics, incomplete outcome data, blinding of outcome assessor, protection against contamination, selective outcome reporting and other risks of bias using the Cochrane Risk of Bias (ROB) Tool. 13 We used the Critical Appraisal Skills Programme (CASP) Economic Evaluation Checklist for health economic studies. 14 For case series,
we used the quality assessment tool produced by the National Institute for Health and Clinical Excellence (NICE). 15 Any disagreements were resolved through discussion and, if necessary, a third reviewer (SD or AS) was consulted.
| Data extraction, analysis and synthesis
Data were independently extracted onto a customized data extraction sheet in DistillerSR by two reviewers (UN, SA, AA, MA, SD or TM), and any discrepancies were resolved by discussion or, if agreement could not be reached, by arbitration by a third reviewer (SD or AS). A descriptive summary with detailed data tables was initially produced to summarize the literature. Where clinically and statistically appropriate, meta-analyses were undertaken using randomeffects modeling. 16 Data were extracted from primary studies, but where these were not available in a suitable format we first contacted authors for data and then if data were still not available we extracted data from previous Cochrane reviews. For outcomes for which it was not possible to produce a meta-analysis, we narratively synthesized data. Heterogeneity statistics are reported with each forest plot.
| Sensitivity analyses and assessment for publication bias
Sensitivity analyses were undertaken for the primary outcomes by comparing the summary estimates obtained by excluding studies considered to be at high ROB.
Publication bias was assessed for these same primary outcomes through the creation of funnel plots, and tested by Egger's regression test and Begg's rank correlation test.
17,18
| Subgroup analyses
A number of subgroup analyses were undertaken, which are listed in the protocol.
| Registration and reporting
This review is registered with the International Prospective Register of Systematic Reviews (PROSPERO): http://www.crd.york.ac.uk/prospe ro/. The registration number is CRD42016035373. The Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist has been used to guide the reporting of this systematic review:
http://www.prisma-statement.org/ (Appendix 2, Supplementary file).
| RESULTS
Our search strategy yielded 5960 titles of which 160 studies (reported in 166 papers) met our overall review eligibility criteria. These eligible papers included 134 double-blind RCTs, 19 health economic analyses and seven case series (Figure 1 ). (Table 1a -c). The majority of studies only included adult participants. A range of allergens were assessed including weed, tree and grass pollens, molds, cat and dog dander, and house dust mites. A range of AIT protocols were utilized. The overwhelming majority of trials only reported on short-term effectiveness (Table S1a-c). A full description of the trials is given in the Data S1.
| Quality assessment

Subcutaneous immunotherapy
Overall, the quality of included studies was high. Thirty-seven studies were found to be at low ROB, eight studies at high ROB, and 16
were judged at unclear ROB (Table S1d) .
Sublingual immunotherapy
The quality of studies was assessed to be low ROB in 26 studies, high ROB in 16 studies and unclear ROB in 28 studies (Table S1e) . In one study, ROB could not reliably be assessed from the translation.
Intralymphatic immunotherapy
Both studies had a low ROB (Table S1f) .
| Primary outcomes
Data on primary outcomes are summarized in Tables S1g-i.
| Symptom scores
Short-term
105 studies reported on the short-term effectiveness of AIT administered by the SCIT (n=51), SLIT (n=52) and ILIT (n=2) routes assessed by symptom scores.
We were able to pool data from 58 SCIT and SLIT studies assessing the effectiveness of AIT by symptom scores. This Sensitivity analysis Sensitivity analysis was performed excluding all studies at high ROB, which demonstrated a SMD of À0.57 (95% CI À0.68, À0.46) ( Figure S1 ).
Assessment for publication bias There was evidence of potential publication bias ( Figure S2 ) which was also suggested by the Begg (P=0.003) and Egger (P=0.003) tests.
Subgroup analyses
Subgroup analyses were undertaken to compare:
• SCIT vs SLIT: SMD À0. AIT, allergen-specific immunotherapy; ILIT, intralymphatic immunotherapy; mo, month; NBS, not better specified; NR, not reported; Rx, treatment; SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy; UR, unclear reporting wk, week; yr, year. • Pre-/coseasonal vs continuous treatment in SCIT for pollen: SMD (Figures S7A and B) , these analyses demonstrating evidence of benefit from both approaches.
• Pre-/coseasonal vs continuous treatment in SLIT for pollens: SMD À0.40 (95% CI À0.48, À0.32) in pre-/coseasonal and SMD À0.55 (95% CI À0.98, À0.11) in continuous ( Figures S8A and B) , these analyses demonstrating a clear benefit associated with both approaches.
• Modified allergen extracts (allergoids) vs unmodified allergen extracts in SCIT: SMD À0.60 (95% CI À0.89, À0.31) vs SMD À0.65 (95% CI À0.93, À0.36) (Figures S9A and B) , these analyses demonstrating evidence of benefit from both modalities
• Aqueous solutions vs tablets in SLIT: SMD À0.42 (95% CI À0.68, À0.15) in aqueous and SMD À0.53 (95% CI À0.73, À0.34) with tablets ( Figures S10A and B) , these analyses confirming benefit with both preparations.
• 
Long-term
To investigate long-term effectiveness, a number of investigators studied a discontinuation period following trials that involved randomization to AIT or placebo in which the superiority of AIT was confirmed. In this longer-term phase, patients were followed up and outcomes were then again assessed at least one year post-discontinuation of AIT.
There were four trials that studied this outcome, one SCIT 42 and three SLIT, 89, 114, 133 all of which were judged to be at low ROB. Meta-analysis of data was not possible. A full descriptive summary of the main findings are provided in the supplement. In summary, all four trials at low ROB found a beneficial effect on the long-term effectiveness of AIT on symptom scores.
| Medication scores
Short-term
Eighty nine studies reported on the short-term effectiveness of AIT administered by the SCIT (n=46), SLIT (n=42) and ILIT (n=1) routes on medication scores.
We were able to pool data from 45 SCIT and SLIT trials. This showed an overall SMD of À0.38 (95% CI À0.49, À0.26), this suggesting a small-to-medium effect in favor of AIT in improving medication scores ( Figure 5 ).
Sensitivity analyses Sensitivity analysis, performed by excluding all studies at high ROB, gave an SMD of À0.35 (95% CI À0.46, À0.24)
( Figure S12 ).
Assessment of publication bias
The Funnel plot revealed evidence of potential publication bias ( Figure S13) Figures 6A and B) , these analyses demonstrating that both routes were effective.
• Figures S15A and B ).
• Seasonal vs perennial allergens for AIT (SCIT and SLIT): SMD ( Figures S18A and B) , indicating that both were effective.
• Pre-/coseasonal vs continuous treatment in SCIT for pollens: • Pre-/coseasonal vs continuous treatment in SLIT for pollens: SMD À0.30 (95% CI À0.42, À0.18) in pre-/coseasonal and SMD 0.00 (95% CI À0.32, 0.33) for continuous ( Figures S20A and B) , these analyses suggesting that pre-/coseasonal was effective and that continuous treatment was ineffective.
Long-term
There were three low ROB trials that assessed this outcome: one SCIT 42 and two SLIT. 114, 133 These three trials are described in detail in the supplement. Overall, one trial found a benefit of AIT (SCIT) on long-term medication scores; the two other SLIT trials did not show a sustained effect.
| Combined symptom and medication scores
Twenty-nine studies reported on the short-term effectiveness of AIT administered by the SCIT (n=20) and SLIT (n=9) routes on combined symptom and medication scores. Two studies (one SCIT and one SLIT) reported on long-term effectiveness in relation to this outcome.
Short-term
We were able to pool data from 15 studies. Meta-analysis found a SMD of À0.49 (95% CI À0.69, À0.30), this suggesting a small-tomoderate effect in favor of AIT ( Figure 7 ). 
Favors active Favors placebo (A) (B)
F I G U R E 6 Meta-analysis of double-blind RCTs comparing medication scores between (A) subcutaneous immunotherapy (SCIT) and placebo groups and (B) sublingual immunotherapy (SLIT) and placebo groups (random-effects models Sensitivity analysis No sensitivity analysis was possible as no studies were judged to be at high ROB.
Publication bias
The funnel plot showed evidence of potential publication bias, ( Figure S24 ) which was also suggested by the Begg (P=0.005) and Egger (P=0.03) tests.
Subgroup analyses Subgroup analyses were undertaken to compare:
• SCIT vs SLIT: SMD À0.51 (95% CI À0.77, À0.26) for SCIT and SMD À0.47 (95% CI À0.81, À0.12) (Figures 8A and B) , these analyses showing a benefit from both SCIT and SLIT.
• Children (<18) vs adults (≥18 years) for AIT (SCIT and SLIT): SMD 
Long-term
We found one SCIT trial 53 and two SLIT trials 109, 133 that reported on this outcome. These are described in detail in the supplement.
Overall, one of the three trials found evidence of a sustained beneficial effect on combined symptom and medication scores. The one trial at an unclear ROB demonstrated a two-year carryover effect of AIT in the active SLIT group that received AIT four months preseasonally for three consecutive seasons but not for the group which received AIT two months preseasonally. (Table S1j and k). The majority of trials (n=29) used one of the disease-specific, validated Rhinitis Quality of Life Questionnaire (RQLQ) instruments. However, one SLIT study (eligible because it reported on other outcomes) used a generic, non-disease-specific tool, the SF- Figure 9 ).
Study name
Statistics for each study Sample size Std diff in means and 95% CI Relative t h g i e w l o r t n o C t n e m t a e r T t i m i l t i m i l s n a e m n
| Allergen challenge models in AIT
A detailed description of environmental exposure chamber, nasal and conjunctival challenge studies is described in the supplement. One SCIT and three SLIT 83, 120, 121 chamber studies demonstrated the effectiveness of AIT. 84, 86, 87, 92, 93, 122, 128, 136, 139, 146, 150 ( Table S1l) were conflicting making it difficult to make clear conclusions. There was no clear evidence of effectiveness in 12 SCIT 21, 23, 35, 38, 42, 45, 55, [62] [63] [64] 70, 72 and four SLIT conjunctival challenges studies 120, 127, 138, 146 ( Table S1m) .
| Cost-effectiveness
Characteristics of studies
We identified 19 eligible studies that reported on health economic evaluations of SCIT and SLIT in both children and adults (Table S1n) . [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] Studies were based in a range of countries. Seven of the studies reported results against disease-specific outcome measures while the remaining 12 reported results based on qualityadjusted life years (QALYs). Thirteen of the studies were based on RCT data or meta-analyses of RCT data. [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [176] [177] [178] Full details are in the supplement. 
Quality appraisal
The quality appraisal of the included studies is detailed in Table S1o .
Main findings
In general, the studies found that AIT, and where defined both SLIT and SCIT, were more effective than standard care including pharmacotherapy, but also more expensive. The studies that compared SLIT with SCIT gave very mixed results not allowing a clear conclusion to be drawn that either treatment was necessarily more effective or more costly than the other from a health system perspective. The studies comparing Grazax (SLIT) and Oralair (SLIT) suggested that Oralair is both more effective and cheaper than Grazax. 165, 167 For those studies based on RCT data conducted from a health system perspective and using QALYs as their outcome measure (n=7), we found that:
• | 1623
Overall interpretation
The seven key studies identified, disregarding the caveats about generalizability, suggested that SLIT and SCIT treatment would be considered cost-effective in this patient population in England at the standard NICE cost-effectiveness threshold of £20 000 (€24 616) per QALY. However, the quality of the studies and the general lack of attention to characterizing uncertainty and handling missing data need to be taken into account when interpreting these results. 162, 164, [166] [167] [168] [169] 177 3.3.4 | Safety
RCTs and case series were eligible for inclusion to consider the safety of AIT.
Randomized controlled trials
Safety data for SCIT and SLIT RCTs are summarized in Table S1p -v.
There was a great variation in reporting of adverse events (AEs) and a number of grading scales including WAO and EAACI were used. As We were able to pool data for the number of patients experiencing a systemic AE for SCIT and SLIT RCTs (n=18) to give a RR of 2.37 (95% CI 1.09, 5.16) ( Figure S3G ).
Local AEs
We were able to pool data for local AEs for 39 SCIT and SLIT RCTs to give an overall RR of experiencing a local AE of 1.78 (95% CI 1.51, 2.11) ( Figure S3H Figure S3I ,J).
We were able to pool data for the number of patients experiencing a local AE for SCIT and SLIT RCTs (n=17) to give a RR of 1.72
(95% CI 1.32, 2.23) ( Figure S3K ).
Case series
Seven large case series were identified. [179] [180] [181] [182] [183] [184] [185] (Table S1w -y) Local (LR) and systemic (SR) AEs were recorded in a range of treatment protocols, including conventional, rush, ultrarush and cluster. In total 4045 patients were included in these case series however only 3541 were patients with allergic rhinoconjunctivitis; we therefore focused on data for these patients.
The case series were conducted in a number of countries including Spain, Colombia, the USA, Germany and Portugal.
The case series highlighted that where modified allergen extracts were used to deliver AIT this was safer in terms of number of AEs reported compared to unmodified extracts. [180] [181] [182] [183] Safety data from the rush 180 and ultrarush 181, 182 protocols were evaluated and are presented in Table S1 w and x. The studies concluded that the frequency of SRs were similar to conventional buildup schedules, but importantly rush and ultrarush protocols were associated with improved patient adherence to treatment by reducing the number of injections required and the cost associated with treatment. Comparable benefits of cluster treatment protocol were also reported in one study. 184 Finally, one case series looked at investigating the number of AEs where patients received either conventional or cluster IT via the SLIT route. AEs were reported in 0.15% of all administered doses in which 9.3% of patients experienced a SR. The study concluded that SLIT was safe in the treatment of allergic rhinoconjunctivitis. 179 No fatalities were reported in any of these studies.
4 | DISCUSSION
| Statement of principal findings
This review of a very substantial body of international trial evidence, many of which were judged to be at low ROB, has found clear evidence that AIT improved all three of our primary outcomes-that is, symptom, medication, and combined symptom and medication scores over the short term. These findings were robust to prespecified sensitivity analyses but evidence of potential publication bias was identified for all three primary outcomes. Although the long-term studies are fewer in number, there was a modest evidence-base in support of the effectiveness of AIT in improving symptom scores after treatment discontinuation for both SCIT and SLIT. The evidence was less clear in relation to the impact on medication and combined symptom and medication scores. SCIT improved disease-specific quality of life. We could draw no clear conclusions on the effectiveness of AIT on nasal and conjunctival challenges and on cost-effectiveness which may be cost-effective in an English NHS setting, but due to the poor quality of the studies this needs to be interpreted with caution. AIT increased the risk of AEs for both SCIT and SLIT, but no fatalities occurred.
| Strengths and limitations
To our knowledge, this is the most comprehensive assessment of AIT in allergic rhinoconjunctivitis ever undertaken. We employed internationally accepted techniques to systematically identify, assess, and synthesize a substantial body of evidence. This involved taking advantage of and building on other recent systematic reviews focusing on distinct modes of delivering AIT.
The limitations of this review need to be considered. First, despite our extensive searches we may not have uncovered all relevant evidence on this subject. Second, we were limited by the heterogeneity in approaches used to assess outcomes, which meant we were unable to pool data from all trials or undertake all the planned subgroup analyses. Furthermore studies for which data was pooled also showed heterogeneity which may be related to the diverse populations studied, protocols followed, products used and duration of trial period. For the subgroup analyses that were undertaken, there was in some cases imprecision which impacted on our ability to draw clear conclusions. These subgroup analyses were indirect comparisons between SCIT and SLIT and the findings should therefore be cautiously interpreted. Third, because of the heterogeneity in scoring systems used, we undertook meta-analyses using random-effects modeling and pooled data using SMDs, which can be difficult to interpret. The absolute size of the SMD was used to guide assessment of the likely effect size demonstrated. 186 Finally, it needs to be borne in mind that there may have been important differences in effectiveness between specific AIT products. Investigating this issue was however beyond the scope of this review. In terms of safety there was heterogeneity in reporting of AEs with many differing scoring systems used due to this we were unable to report this outcome as originally planned using only the WAO grading system.
| Implications for policy, practice, and research
Our findings clearly show that AIT is effective in improving the three patient-reported outcomes that represented our primary outcomes, at least over the short term, and that AIT should therefore be considered in the management of patients with allergic rhinoconjunctivitis.
Greater standardization of trial designs and reporting techniquesin particular, in relation to choice of outcomes and their reporting so as to facilitate evidence syntheses and key subgroup analyses, would greatly help to advance the research base underpinning AIT. We therefore appreciate initiatives of the EAACI in, for example, harmonizing and standardizing clinical endpoints in AIT 187 or determining threshold level of relevant pollen seasons for assessing clinical effect sizes. 188 We also wish to highlight the need for additional studies focusing on long-term outcomes and on studies of ILIT and other novel modes of delivery. We hope that future researchers will build on the findings from this systematic review and aim to fill key evidence gaps and areas of continuing uncertainty.
The findings from this review will be used to inform the development of recommendations for EAACI's Guidelines on AIT for Allergic Rhinoconjunctivitis.
| CONCLUSIONS
AIT is effective in achieving clinically important short-term improvements in symptom, medication, and combined symptom and medication scores. There is a limited body of evidence on the longer-term effectiveness of AIT in improving symptom scores.
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